A cloud continues to follow cannabis. Like other biases, ignorance, political populism, and moralism continue to support fears and contempt.
The stigma combines several strains of racial prejudice, reefer madness, and a few legitimate concerns. But, it is 2018. Cannabis is valued for medical benefits in more than half the United States and allowed for recreational use in an increasing number. So, why is there still such a negative stigma surrounding cannabis?
The public is misinformed in several ways. The lies and confusion may begin with teenagers. They are given to exaggerating experience in getting their stash, overstating their user experience, and boasting of effects that never really happened. It’s typical adolescent behavior to surround their experience with drama and mystery. Without the rebellion, there is nothing cool about cannabis.
Critics of cannabis use as marijuana or derivatives proceed from the assumption that cannabis does belong on the FDA’s list of Schedule I drugs. They assume it belongs with cocaine, heroin, and other hard drugs. That assumption colors their research and arguments. After all, because it is Schedule I, cannabis must behave in the same way.
Still, cannabis activists Americans for Safe Access (ASA) has succeeded in getting the DEA to remove a 45-page document filled with misinformation from its website under the Information Quality Act.
However, even some cannabis advocates contribute to the misinformation by cherry-picking the research and making counter-arguments that are more political than factual. They ignore some legitimate concerns with Cannabis User Disorder, chronic and heavy use, and increased concerns about driving under the influence and cannabis use during pregnancy.
Unfortunately, the FDA’s position on cannabis, directly and indirectly, affects the possibility of research. Sources are restricted, funding is discouraged, and experiments on humans are rare. Even, existing quality research lacks a central focus, much of it proving redundant. Only the research directed by Big Pharma appears to involve the long-term, double-blind discipline required of the scientific method.
The negative stigma surrounding cannabis is largely attributable to its introduction to the U.S. across the Mexican border dating to the border wars that ran into the 1930s. Politicians linked cannabis with concerns about immigration.
By the time, these voices gained influence, cannabis was already popular among mobile cultures like musicians and artists. It was inebriating and creative, and it was just enough off the moral high road to make it more attractive among populations that the politicians disdained.
Cannabis grew in availability about the same time that U.S. politics found support in populist appeals to all sorts of tea totaling prohibitionists. Preachers, in and out of the clergy, found appeal in banning alcohol and other “vices.” It was a time for Father Charles K. Coughlin, Louisiana Gov. Huey Long, the Klux Klan, and more. Their exaggerated rhetoric inflamed cultures too ready to find a culprit in cannabis.
By 1938, the nation’s moviegoers were spooked by “Reefer Madness.” The Motion Picture Production Code of 1930 has banned the portrayal of drug use in the film. “Reefer Madness” exploited the code by creating the most memorable sensationalized anti-drug movie that now appears hilarious. Nonetheless, it effectively spread the impression that marijuana was corrupting, maddening, and hallucinogenic. According to the film, cannabis led immediately to madness, sexual profligacy, and heavier drugs.
And, as you go through the 1940s and 50s, Senator Joseph McCarthy’s hearings appealed to the public in cheap, emotional, and negative appeals to the populist fears of Communism. The same fears connected cannabis with Civil Rights efforts and anti-war conflicts. Now, cannabis terror continues to ruffle feathers at the edge of Trump era politics.
In short, reefer madness makes cannabis a convenient target when looking for populist issues concerned with evil forces at work everywhere.
Need to fight the bias
The stigma surrounding cannabis helps make its market. If there is something naughty about it, it will always attract customers. There is a danger in broadscale legalization that cannabis would become so clean it would lose its fascination.
But, if advocates are to succeed in further legalization, if medical cannabis is to reach the public that needs it, the assorted negative biases must be reduced or eliminated.
The cannabis press must address negative issues as well as the positive:
- According to The New York Times, “in Colorado, the rates of marijuana exposure in young children, many of them toddlers, have increased 150 percent since 2014, when recreational marijuana products, like sweets, went on the market legally.”
- CBSLocal (Denver) quoted headlines from a Rocky Mountain High Intensity Drug Trafficking Area report on some results following 2014 legalization in Colorado:
♦ Marijuana-related traffic deaths up 32%.
♦ Almost 20% of all traffic deaths were marijuana related.
♦ Marijuana-related emergency department visits up 29%.
♦ Marijuana-related hospitalizations increased 38%.
♦ Marijuana-related calls to the rocky mountain poison center up 72%.
- Newsweek reported, “Other symptoms of Colorado’s pot culture include increased use among teens, resulting in educational problems in middle schools and high schools, a spike in ‘edibles’-related emergency room visits, consumption by children and pets resulting in illness and death and regulatory confusion surrounding public consumption and enforcement.” High school expulsions have increased as has the Denver homeless problem.
The cannabis media can do more to acknowledge these real issues. Such reporting adds credibility to their work. These issues are management problems, not political:
- The public has a right to research supported information on medical marijuana and recreational marijuana. They should know the contents of products, the quality standards, and the potential side-effects or risks of using cannabis with other inebriants or prescription medications.
- The public has a need to know about the pros and cons of various strains, how to treat overindulgence, and how to avoid dependency. They have a right to know about the progress in research and development of cannabis-derived pharmaceuticals.
- The public wants the clear information that will help them understand and advocate cannabis legislation. They will find it easier to promote passage of related legislation if they have confidence in the data at hand. It’s just so much easier to support something you have mastered.
It’s 2018, after all!
Yes, it’s 2018, and it’s been a long time getting approved cannabis consumption. It’s not likely that momentum will change direction. It’s not likely what is done will come undone. But, the cannabis industry would be smart to frame strategies, solutions, and standards that would make the content and approach consistent and comprehensive.